NASH has the potential to advance to liver fibrosis, cirrhosis and liver cancer; it is important to note that NASH Secondary, which is induced by drugs or
by Y Sumida 2024 Cited by 691PFD can be repositioned as an antifibrotic drug for human NASH. Diabetic NASH patients should be preferentially treated with novel drugs
By 2024, NASH is projected to overtake hepatitis C as the leading cause of liver transplants in the USA. There are still no approved drugs for treating NASH. Although there are approximately 196 agents of investigational NASH therapies in various stages of development, we here mainly review phase 3 drug candidates in the pipeline for NASH.
by G Shao 2024 Cited by 18Some drugs have been found to be associated with the inhibition of NASH-HCC progression, and thus, these drugs may be effective in treating NASH-driven HCC.
However, primarily anti-NASH drugs that have no direct antifibrotic effect could, theoretically, result in a subsequent reduction of fibrosis if a sustained resolution of NASH is achieved. Conversely, purely antifibrotic drugs with no anti-NASH activity and no interference with insulin resistance will leave the triggers for fibrogenesis
Nonalcoholic steatohepatitis (NASH) drugs market-article.
by B Staels 2024 Cited by 29(NASH). Extensive evidence of preclinical anti-NASH activity has spawned the clinical testing of different PPAR-modulating drugs as NASH.
Our Medicine NASH Overview Resources Investors Media Overview Press NASH. Overview Resources. NASH/MASH: A Leading Cause of Liver Related
In its pivotal study, the drug topped placebo at improving fibrosis with no worsening of NASH but showed no significant benefit on NASH
Comments